Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 6, H.C. Wainwright reduced its price target on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $80 to $60 but kept its Buy rating on the stock. The reduced price target still represents a significant upside from the current price. This update comes after the company announced that its two pivotal trials for setrusumab in osteogenesis imperfecta (OI), Cosmic and Orbit, ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class acti ...

We recently published 10 Stocks on Fire Ahead of 2026. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best performers on Tuesday. Ultragenyx rebounded by 15.52 percent on Tuesday to close at $22.78 apiece as investors resorted to bargain-hunting following the previous day’s steep 46 percent fall, dragged by disappointing clinical trial results for its brittle bone disease treatment. In a statement on Monday, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said that two of its phase 3 clinical tr ...

他补充称，该公司维持其 2027 年盈利指引，并将在 2026 年初明确削减开支的计划。 Raycroft 还指出，对于刚刚在成骨不全症三期临床试验中失败的候选药物 setrusumab，希望或许并未完 全破灭。他表示："美国食品药品监督管理局(FDA)最近将'骨密度(BMD)'列为骨质疏松症的替代指标， 我们认为这可能会影响 Ultragenyx 及合作伙伴 Mereo BioPharma(MREO)与该机构的后续讨论。" 然而，花旗对 Ultragenyx 的态度则没那么乐观。该行已将该公司从其 90 天内上行催化剂观察名单中移 除。 智通财经APP获悉，由于针对罕见骨病资产的两项后期临床试验失败，Ultragenyx Pharmaceutical (RARE.US) 周一收盘下跌约 42%，但投行杰富瑞发布报告称，鉴于其管线中的其他候选药物，该公司 有望在 2026 年迎来反弹。 杰富瑞分析师 Maury Raycroft，给予 Ultragenyx "买入"评级并表示，公司明年可能会从 apazunersen (GTX-102) 的三期数据公布中获益，这是一种用于治疗天使综合征(Angelman sy ...

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential securities fraud and unlawful business practices following disappointing Phase 3 study results for its treatment setrusumab, which led to a significant drop in stock price [1][3][4]. Group 1: Company Performance - Mereo announced results from two Phase 3 studies for setrusumab, a treatment aimed at conditions affecting bone metabolism [3]. - Neither study met the primary endpoints of reducing the annualized clinical fracture rate compared to placebo or bisphosphonates, although both achieved secondary endpoints related to improvements in bone mineral density with strong statistical significance [3]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, a decrease of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Mereo investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

Key Points A Wells Fargo analyst cut his price target on Ultragenyx stock, though it still implies significant upside from yesterday's closing price. Ultragenyx reported yesterday that two Phase 3 studies failed to achieve primary endpoints for setrusumab. Despite the Wells Fargo analyst's positive outlook, Ultragenyx stock should only remain a consideration for those comfortable with more speculative investments. 10 stocks we like better than Ultragenyx Pharmaceutical › While Ultragenyx Pharmac ...

“We expect the minutes to the December meeting to note ongoing disagreement among FOMC participants about the appropriate policy path over the near term,” Goldman Sachs economists wrote in a note this week.Today, market watchers will pay close attention to the publication of the minutes from the Fed’s December 9-10 meeting. The minutes will be scrutinized to assess policymakers’ appetite for additional rate cuts. The FOMC lowered its benchmark rate this month for the third time in a row, though officials’ m ...

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a reading of 49.3, down from 52.5 [5] - U.S. stocks settled lower on Monday, with the Nasdaq Composite falling more than 100 points during the session [1] Stock Performance - Nvidia Corp. shares fell more than 1% on Monday after gaining last week [1] - The S&P 500 recorded a 1.4% increase last week, marking its fourth weekly surge in five weeks, while the Dow and Nasdaq also added over 1% [1] - The Dow Jones closed lower by around 249 points to 48,461.93, the S&P 500 slipped 0.35% to 6,905.74, and the Nasdaq Composite declined 0.50% to 23,474.35 during Friday's session [4] Company-Specific News - Mereo BioPharma Group plc shares dropped 88% on Monday after its Phase 3 studies for setrusumab in Osteogenesis Imperfecta did not achieve statistical significance against primary endpoints [2] Economic Data - U.S. pending home sales increased by 3.3% month-over-month in November, following a revised 2.4% gain in October, exceeding market estimates of a 1% gain [3] - Most sectors on the S&P 500 closed negatively, with consumer discretionary, materials, and financials stocks recording the largest losses, while energy and real estate stocks closed higher [3]

Group 1 - Both Ultragenyx and Mereo BioPharma experienced record selloffs in their shares following disappointing trial results for setrusumab [1]

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.43% to 48,500.27 while the NASDAQ slipped 0.52% to 23,470.77. The S&P 500 also fell, dropping, 0.34% to 6,906.49.Check This Out: Top 2 Risk Off Stocks That May Collapse In DecemberLeading and Lagging SectorsEnergy shares rose by 1.1% on Monday.In trading on Friday, materials stocks fell by 1.3%.Top HeadlineU.S. pending home sales jumped by 3.3% month-over-month in November, ...